ForSight Vision5 closes $15 million funding round, completes phase 2 study enrollment
ForSight Vision5 closed a series C round of funding, which raised $15 million, and completed enrollment in a phase 2 clinical study for the Helios ocular insert, a press release said.
The company, which is developing noninvasive products to replace eye drops and provide sustained therapy for anterior segment eye diseases, completed enrollment of more than 160 subjects in a randomized, active controlled study of the Helios insert in patients with glaucoma and ocular hypertension, according to the release.
The funding was led by H.I.G. BioVentures. Returning investors included Morgenthaler Ventures, Versant Ventures, Technology Partners and Delphi Ventures.